Promega builds plant to produce regulated products

Published: 29-Aug-2011
Manufacturing Analysis

Including sample preparation systems and reagents

Promega builds plant to produce regulated products
Promega Corporation, based in Madison, Wisconsin, US, has held a ground-breaking ceremony for a new cGMP facility to support business growth and customers who need FDA-regulated molecular biology products. These include sample preparation systems and reagents, which are part of diagnostic and medical tests sold by human diagnostic test providers.

The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.

‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.

Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.

Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Read more
Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. GLP-1 news round-up: what's happened in weight loss Lilly's retatrutide posts strong Phase III results, Novo Nordisk pays up to $2.6bn for an oral candidate and nasal and AI-designed approaches advance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II) Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)

As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
Analysis
Countable Labs and Promega to facilitate end-to end biological sample preparation and rare variant detection

Countable Labs and Promega to facilitate end-to end biological sample preparation and rare variant detection

Joint offering creates state-of-the-art workflow uniting Promega’s fast and reliable nucleic acid extraction instrumentation with Countable Labs’ accurate and easy-to-use Countable PCR technology to deliver accuracy across research
Ingredients
Promega unveils cellular target engagement technology

Promega unveils cellular target engagement technology

TarSeer BRETSA platform enables early-stage studies for difficult proteins in drug discovery
Manufacturing
Promega opens new Shanghai facility

Promega opens new Shanghai facility

Provides additional r&d and cGMP manufacturing capabilities
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Subscribe now